Gbola Amusa
Stock Analyst at Chardan Capital
(1.93)
# 2,984
Out of 4,735 analysts
61
Total ratings
40%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $4.40 | +1,036.36% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $1.53 | +4,311.76% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $14.70 | +17,757.14% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $3.26 | +9,102.45% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.62 | +7,193.35% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $28 → $30 | $0.73 | +4,003.97% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $14.91 | +570.69% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.44 | +10,316.67% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $5.88 | +750.34% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $23.59 | +90.76% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $151.55 | -24.12% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $41.51 | +140.91% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $35.89 | +164.70% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $9.51 | +57.73% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $7.57 | +1,617.31% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $2.15 | +4,551.16% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $605.58 | -99.67% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.94 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $687.80 | -49.11% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $4.40
Upside: +1,036.36%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $1.53
Upside: +4,311.76%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $14.70
Upside: +17,757.14%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $3.26
Upside: +9,102.45%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.62
Upside: +7,193.35%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $28 → $30
Current: $0.73
Upside: +4,003.97%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $14.91
Upside: +570.69%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.44
Upside: +10,316.67%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $5.88
Upside: +750.34%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $23.59
Upside: +90.76%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $151.55
Upside: -24.12%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $41.51
Upside: +140.91%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $35.89
Upside: +164.70%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $9.51
Upside: +57.73%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $7.57
Upside: +1,617.31%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $2.15
Upside: +4,551.16%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $605.58
Upside: -99.67%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.94
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $687.80
Upside: -49.11%